Media OutReach
Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves
Strategic realignment powering Bora’s dual-engine businesses model
HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025.
Quarterly Business and Financial Highlights
- Company reported quarterly basic EPS of NT$5.09, with a loss per share of NT$1.49 from discontinued operations. Operating income reached NT$1,063 million and net income for continued operations came in at NT$822 million, resulting in quarterly EBITDA of NT$1,283 million, well on track to reclaim 2023 core P&L indicators.
- By the end of 3Q25, Bora’s operational integration and strategic streamlining efforts have been fully executed, meeting all targeted objectives. This milestone has led to a record-high CDMO business profitability, clear evidence that Bora’s dual-engine model is now entering its next phase of balanced but scalable growth.
- Fueled by expanded capacity and the addition of new dosage forms, Bora’s CDMO business grew 56.5% year-to-date through 3Q25, reaching over NT$7.3 billion and returning to a sequential growth trajectory.
- Pharma sales revenues fluctuated as legacy inventory phased out, and new products are still awaiting approvals. Generics portfolio competitiveness remains a key focus area in the near term. Led by Vigafyde, Bora’s rare disease portfolio continued to gain impressive market share with the vigabatrin franchise across three dosage forms continues. The Company targets to file its next specialty pharma product by year end to accelerate the rare neurology disease business. The Company also targets to market branded Deflazacort tablets by 2025 year end as a new driver for the business.
- The Company expects NTD to remain in the range of NTD 30-31 per USD for its operational planning.
- Share capital increased 19.99% during the quarter from stock dividend distribution, employee stock option exercise and convertible bond conversions.
- The Board approved Level-1 ADR issuance with each ADR share corresponding to 1/5 common share and total ADR issuance <10% of outstanding shares to enhanced market trust and investor service.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “Bora executed a record level of post-merger CAPEX investment in 2025 and we are progressing in line with our strategic plan. We have expanded our Maryland aseptic fill/finish capacity by approximately 10% while solid and liquid dosage capacity in Minneapolis and Mississauga grew around 3%. The investments allowed Bora to increase our operational efficiency and increase revenue per headcount in the CDMO business by ~30% during the quarter compared to beginning of the year.
The CDMO backlog rose to US$296 million, driven by 27 new contracts and over 20 new molecules year-to-date, providing solid visibility into 2026 with 72% commercialized projects. Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio, while paving the way for selective in-house manufacturing of specialty assets in the U.S.
As we look ahead, Bora is entering a phase of disciplined expansion and broader global recognition. Across our CDMO facilities in Asia and North America, we continue to actively navigate tariff and geopolitical challenges and turn them into new opportunities, strengthening supply chain resilience, and deepening collaboration with multinational partners.
On the pharma sales side, we continue to shed legacy low margin generics, increase our cashflow, and focus on our high-value generics pipeline, with certain PIV opportunities progressing to maturity in 2026. We remain dedicated on enhancing portfolio quality and increasing our Branded assets through selective specialty drugs, in order to build a more predictable and margin-accretive revenue base that mitigates product commoditization and price degredation.
In parallel, we are expanding our capital-market reach into the United States through the OTCQX Level-1 ADR program. We believe the Bora ADR will improve access and transparency for global institutional investors, while enabling overseas employees to participate in Bora’s growth. With no dilution and increasing visibility, we are laying the foundation for a stronger and more global 2026, defined by scaled growth, operational synergies, and increasing investor confidence.
3Q2025 Operational Achievements & Full Year Outlook
Global CDMO Operations
Global CDMO Operations (excluding intercompany orders from Upsher-Smith) revenues arrived at NT$1.78 billion in the third quarter and back to the sequential growth zone, representing approximately 37.13% of total revenue. A total of 418 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 33%. Year-to-date, CDMO revenues grew 18.98% over last year and reached NT$5.27 billion. Bora continues to execute on expanding this customer base to enhance business visibility and stability.
- As the Company ramps up its Maple Grove site, the momentum for U.S. manufacturing has been encouraging. Several clinical-stage clients are now transitioning into long-term strategic partnerships, with project scale and client size both increasing. Maple Grove is well positioned to be the Center of Excellence for scale-up and U.S. supply-chain integration for Bora.
- Large molecule CDMO operation revenues saw nearly 50% increase over the previous quarter, driven by one new ADC client and several change orders in addition to Cipla’s own labeled product launch under the collaboration agreement. Positioned as a one-stop CDMO platform alongside Bora Pharmaceuticals, Bora Biologics is now fully accelerating its CDMO operations
Pharma Sales Operations
Pharma Sales Operations in the third quarter reached a revenue of NT$3.02 billion, down 6.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 62.83% of total revenues.
- Discontinued loss per share (from the closure of the Plymouth production area) reflected the clearance sale of higher-cost inventories from Upsher-Smith’s legacy generics and internal supply transfer delayed by regulatory hurdles. These inventory clearance sales are now nearing completion. The greater-than-expected pricing pressure across our low margin generics reinforces the need to accelerate Bora’s transition toward higher-value and Branded specialty pharma products.
- The Vigabatrin franchise market share expansion continues with the “total patient” indicator seeing breakthrough in October.
- Bora continues to focus on DEE (Developmental and Epileptic Encephalopathies), where legacy compounds fail to meet significant unmet needs. The market is poised for new NCE entrants, expanding the addressable opportunity to roughly US$10 billion over the next 3–5 years. Bora aims to capture this growth through a Ready-to-Use 505(b)(2) pipeline and branded generics.
Recent Investor Conference
Bora will host an English online earnings call at 8:00 p.m. Taiwan time on Nov. 13th, 2025, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:30 p.m. on Nov. 14th, 2025. Both events will cover the company’s Q3’25 financial and business results and outlook.
English Online Earnings Presentation Link: https://events.q4inc.com/attendee/477519089
Bora will participate in the JP Morgan Healthcare Conference in January in San Francisco. For 1:1 meetings with management, please contact your JP Morgan representative.
Bora 2025 Earnings Schedule
Q4 2025: Expected in the 2nd week of March 2026
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, visit www.bora-corp.com.
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Media OutReach
Sun Group debuts at SITF 2026 with exclusive Phu Quoc flight deals and a fresh vision for Vietnam tourism
A special highlight is Sun Group’s unveiling of its new development vision for Phu Quoc in the lead‑up to APEC 2027, presented directly to Korean partners and visitors.
From the first day of the fair, Sun Group’s booth has welcomed a steady stream of visitors. Throughout the four-day event, the booth has organized B2B and B2C networking activities, customer consultations, and introductions to tourism, resort, and aviation products. Interactive programs, including mini-games, souvenir giveaways, and tailored offers for the Korean market, have kept the atmosphere lively for hours, with a continuous flow of engaged visitors.
During SITF (June 4–7), travelers have the opportunity to receive a 20% discount on the base fare when booking Sun PhuQuoc Airways tickets via the airline’s website or app. The offer applies to the Korean market for one‑way or round‑trip journeys from Korea to Phu Quoc. Limited to 200 Economy Class discount codes, it is valid for flights from June 15 to October 24, 2026 (excluding peak periods as defined by the airline).
Visitors also have the chance to win attractive prizes through booth activities, including free round‑trip air tickets on the Seoul–Phu Quoc route (ICN–PQC) and resort vouchers at hotels within Sun Group’s ecosystem.
By combining destination promotion with airline incentives, Sun Group aims to further encourage South Korean tourists to choose Vietnam for their upcoming holidays, especially Phu Quoc, which is entering a new era of large‑scale investments in projects, products, and experiences all aimed at APEC 2027.
Hashtag: #SunGroup
The issuer is solely responsible for the content of this announcement.
About Sun Group
Vietnam’s leading private economic group, Sun Group operates an integrated ecosystem spanning tourism, entertainment, hospitality, real estate, infrastructure, and aviation. Guided by the mission “Enhancing the beauty of the lands,” the Group shapes iconic destinations nationwide through its Sun World entertainment brand. In the aviation sector, Sun Group develops a hub-and-spoke model anchored by Phu Quoc, driven by strategic airport investments and Sun PhuQuoc Airways.
Media OutReach
Technology + Scenario + Supply Chain = A New Benchmark for Regional Zero-Carbon Smart Transportation
Wing Kai New Energy X QIJI Energy X C&D Hi-Tech
HONG KONG SAR – Media OutReach Newswire – 5 June 2026 – The 19th (2026) International Photovoltaic Power Generation and Smart Energy Exhibition & Conference (SNEC 2026) was grandly held from June 3 to 5, 2026, at the National Exhibition and Convention Center (Shanghai). Attracting over 3,000 exhibitors from 95 countries worldwide, the event stands as the largest and most influential professional grand gathering for the photovoltaic and energy storage sectors across Asia and globally.
During the exhibition, Mr. Yiu Wang Lee, Chairman of the Board of Wing Lee Development Construction Holdings Limited (“Wing Lee” or the “Group”, stock code: 9639.HK); Mr. Cai Huihui, General Manager of Wing Kai New Energy Technology Co., Limited (“Wing Kai New Energy”); Mr. Wang Yi, Key Account Manager of QIJI Energy; Mr. Xu Jun, Overseas Energy Storage Commercial Director of Contemporary Amperex Technology Co., Limited (CATL); and Mr. You Yuxian, ASEAN Regional Energy Storage Sales Director of CATL, jointly visited the exhibition booth of C&D Hi-Tech. The delegation engaged in in-depth discussions with the team led by General Manager Mr. Zhan Shengli, focusing on battery swapping station projects in Hong Kong and Southeast Asia. By integrating multi-party resources, the teams successfully finalized and signed a Strategic Cooperation Agreement.
Through this signing, the three parties will join forces to address and resolve the industry pain points of overseas markets regarding regulatory compliance, engineering infrastructure, and supply chain coordination. The collaboration represents a deep integration of QIJI Energy’s cutting-edge battery swapping solutions, Wing Kai New Energy’s localized infrastructure and operational capabilities across Hong Kong and Shenzhen, and C&D Hi-Tech’s robust global resource allocation strengths. Moving from single-project development to an ecosystem of mutual win-win, this partnership will significantly enhance the delivery efficiency of green energy across Hong Kong, Macau, and the Southeast Asian region, setting a brand-new benchmark for regional zero-carbon smart transportation.
As a subsidiary of Wing Lee, Wing Kai New Energy has been rooted in Hong Kong since its inception while radiating its presence globally, deeply cultivating sustainable clean energy solutions. Addressing the acute pain points in the Greater Bay Area and Southeast Asian markets, where rapid fluctuations in energy prices have led to surging cost pressures for logistics distribution enterprises, Wing Kai New Energy will focus on urban distribution logistics battery swapping businesses in the future. The company plans to integrate site resources, infrastructure, and operations to fill the gap in regional infrastructure. We firmly believe that this cooperation will effectively bridge the cross-border green energy eco-link, accelerate the construction of a green energy service network, and contribute solidly to the realization of the “dual carbon” goals. Meanwhile, we sincerely invite more partners to join the Zero-Carbon Smart Alliance to jointly advance sustainable development.
Hashtag: #WingLee
The issuer is solely responsible for the content of this announcement.
About Wing Lee Development Construction Holdings Limited
Deeply rooted in Hong Kong, Wing Lee is an established contractor engaged in civil engineering, electrical and mechanical engineering, and new energy businesses, and has participated in various large-scale landmark projects in Hong Kong. The Group’s civil engineering business specialized in site formation waterworks as well as road and drainage works, while its electrical and mechanical engineering business specializes in power system-related projects and emergency maintenance works. In recent years, the Group has actively expanded into the new energy sector, undertaking solar photovoltaic projects, distributing various electric commercial vehicles and electric construction machinery, and engaging in the construction and subsequent maintenance of charging piles, battery swapping, recycling, and energy storage businesses. In 2025, Wing Lee Construction, together with SANY Group Co., Ltd. and CATL, among other industry giants, founded the “Zero-Carbon Smart Alliance” to develop full-industry-chain solutions for photovoltaics, energy storage, charging and battery swapping, and smart applications in green transportation.
The delegation of over 70 business and institutional leaders from Hong Kong and the Chinese Mainland is the largest and most diverse overseas mission led by the current term of the HKSAR Government so far.
Speaking to the media in Uzbekistan yesterday (June 4), Mr Lee set out the three main objectives of the visit: further explore emerging markets and lay the foundation for long-term economic and trade development; strengthen government-to-government (G2G) relationships and promote closer bilateral co-operation; and build a “hub-to-hub” model of co-operation.
He said the visit had been successful, yielding achievements in eight areas, including:
- Establishing high-level contacts and ties between the HKSAR Government and the Governments of Kazakhstan and Uzbekistan, and reaching consensus on co-operation in multiple areas;
- A total of 96 co-operation agreements and memoranda of understanding (MoUs) were reached during the visit (61 with Kazakhstan, 35 with Uzbekistan), involving specific amounts exceeding US$1.65 billion in total;
- The governments agreed to commence bilateral discussions on agreements in various areas;
- Deepening project matching and research collaboration between Hong Kong and Central Asian region in areas including finance, innovation and technology (I&T), and aviation;
- Demonstrating Hong Kong’s effective role as a platform for going global and achieving substantial results, with Hong Kong and Mainland enterprises joining forces in tapping new markets and bringing synergistic advantages into full play;
- Facilitating more convenient people-to-people exchanges by promoting direct flights, aviation and transport co-operation, and extensions to the mutual visa-free period;
- Promoting exchanges in education, talent and culture to further deepen people-to-people bonds; and
- Advancing a hub-to-hub co-operation model to open up broader room for co-operation between Hong Kong and the Central Asian region.
While in Tashkent (June 3-5), Mr Lee met with local leaders, government officials and business representatives to deepen co-operation between Hong Kong and Uzbekistan in areas including trade, investment, finance, I&T, and people-to-people exchanges.
Mr Lee held meetings with the President of Uzbekistan, Shavkat Miromonovich Mirziyoyev, his Advisor on Strategic Development, Sardor Umurzakov, the Prime Minister, Abdulla Nigmatovich Aripov, as well as the Deputy Prime Minister, Jamshid Khodjayev, to exchange views on furthering mutual co-operation.
Mr Lee highlighted that under the “one country, two systems” principle, Hong Kong enjoys both the China advantage and the global advantage. He said that Hong Kong would continue to play its roles as a “super connector” and a “super value-adder” to further deepen co-operation and exchanges with Uzbekistan on various fronts in line with Uzbekistan’s goal of achieving high-quality development.
Earlier (June 3), Mr Lee met with the Minister of Foreign Affairs of Uzbekistan, Bakhtiyor Saidov, after which they jointly witnessed an exchange of notes between the two places on a mutual visa-free arrangement, which would allow a visa-free period of 30 days for visitors from both sides.
“Moreover, we are glad to have initialed the Air Services Agreement with Uzbekistan, and look forward to launching direct passenger flights between the two places soon,” Mr Lee said, during a high-level business dinner (June 4). The Chief Executive pointed out that Hong Kong and Uzbekistan are important trade and investment gateways to their respective regions – the Asia-Pacific and Central Asia.
“It helps that we are all believers in the Belt and Road (B&R) Initiative, a modern expression of the ancient Silk Road spirit,” Mr Lee said. “Today, China is Uzbekistan’s largest trading partner, and the two countries work closely on major infrastructure and connectivity projects that are revitalising the Silk Road. Hong Kong is a pivotal player in the B&R Initiative, thanks to our world-class professional and financial services expertise.”
The delegation also toured the IT Park Uzbekistan and the Center for Islamic Civilization before concluding its visit in Tashkent.
Hashtag: #HongKong #BrandHongKong #CentralAsia #Kazakhstan #Uzbekistan
https://www.brandhk.gov.hk/
https://www.linkedin.com/company/brand-hong-kong/
https://x.com/Brand_HK/
https://www.facebook.com/brandhk.isd
https://www.instagram.com/brandhongkong
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn